Recombinant staphylokinase - Supergene

Drug Profile

Recombinant staphylokinase - Supergene

Alternative Names: Fortelyzin; Forteplase; Gene modified staphylokinase - Supergene; Recombinant nonimmunogenic staphylokinase - Supergene; Recombinant staphylokinase variant - Supergene

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Supergene
  • Class Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke
  • No development reported Myocardial infarction

Most Recent Events

  • 11 May 2017 Phase-III clinical trials in Stroke in Russia (IV) (NCT03151993)
  • 05 Apr 2017 No recent reports of development identified - Phase-III for Myocardial infarction in Russia (IV)
  • 01 Oct 2014 Phase-III clinical trials in Myocardial infarction in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top